ResMed releases Q2 FY17 results

27/01/2017 07:52:00

This video is not supported on your device. Click here for the original version.

ResMed (ASX:RMD) has announced its latest Q2 results for the period ending 31 December 2016.

Revenue for the quarter was up 17 percent compared to Q2 of FY16, increasing to $530.4 million.

Earnings came in at $0.73 per share, consistent with the corresponding period last year.

Gross margin increased by 0.2% to 58.3%, and was attributed in part to manufacturing and procurement efficiencies.

ResMed reported a net profit of $474.6M at 30 June 2016.